Vera Therapeutics, Inc. (VERA) – What Are Analysts Saying About This Stock?

Vera Therapeutics, Inc. (NASDAQ:VERA) has been given a consensus rating of “Moderate Buy” by the fifteen analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $76.86.

A number of equities analysts recently weighed in on VERA shares. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a research report on Wednesday, July 8th. Raymond James Financial reiterated a “strong-buy” rating on shares of Vera Therapeutics in a report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Bank of America raised their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Finally, TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, September 15th.

Vera Therapeutics Trading Down 0.2%

Shares of VERA stock opened at $26.74 on Thursday. Vera Therapeutics has a fifty-two week low of $23.05 and a fifty-two week high of $56.05. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The stock’s fifty day moving average is $32.52 and its two-hundred day moving average is $35.73. The firm has a market capitalization of $1.93 billion, a P/E ratio of -4.56 and a beta of 1.06.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same quarter in the previous year, the business posted ($1.20) EPS. Research analysts expect that Vera Therapeutics will post -6.45 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total transaction of $684,500.00. Following the transaction, the chief executive officer owned 235,244 shares in the company, valued at approximately $8,704,028. This trade represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Eversept Partners LP raised its position in Vera Therapeutics by 9.4% in the fourth quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock valued at $155,581,000 after purchasing an additional 264,468 shares during the period. Armistice Capital LLC lifted its stake in shares of Vera Therapeutics by 22.0% in the 4th quarter. Armistice Capital LLC now owns 653,796 shares of the company’s stock valued at $33,108,000 after purchasing an additional 117,796 shares during the last quarter. First Turn Management LLC lifted its stake in shares of Vera Therapeutics by 69.7% in the 4th quarter. First Turn Management LLC now owns 601,774 shares of the company’s stock valued at $30,474,000 after purchasing an additional 247,245 shares during the last quarter. Elmind Capital LP purchased a new position in shares of Vera Therapeutics during the 4th quarter worth $24,434,000. Finally, Braidwell LP grew its holdings in shares of Vera Therapeutics by 7.8% during the 2nd quarter. Braidwell LP now owns 564,724 shares of the company’s stock worth $24,232,000 after purchasing an additional 40,900 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s lead product candidate is atacicept, an investigational fusion protein designed to inhibit two immune signaling molecules, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which contribute to the survival and activity of antibody-producing B cells.

Vera is primarily studying atacicept as a potential treatment for immunoglobulin A nephropathy (IgA nephropathy), a chronic kidney disorder caused by the buildup of IgA immune complexes.